Harnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian Cancer

Sarah P. Blagden(Churchill Hospital)

Frontiers in Oncology

June 30, 2015

10.3389/fonc.2015.00149

Cited by 65

Related Papers

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

|Nature reviews. Cancer|2015|1.4k

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

|The Lancet|2019|223

Performance status score: do patients and their oncologists agree?

|British Journal of Cancer|2003|222

La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs

|eLife|2017|201

Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

|Clinical Cancer Research|2011|168